Longeveron will present at the H.C. Wainwright 28th Annual Global Investment Conference, running from 14 to 16 September 2026 in New York City, with the company’s presentation scheduled for Monday, 14 September, from 1:00 to 1:30 p.m. Eastern Time, and a webcast available via the company’s events and presentations page.
Longeveron is a clinical-stage biotechnology company developing regenerative medicine cellular therapies. According to the company, its lead investigational product is laromestrocel (Lomecel-B), an allogeneic mesenchymal stem cell therapy isolated from the bone marrow of young, healthy adult donors, and the company claims laromestrocel has pro-vascular, pro-regenerative, anti-inflammatory and tissue repair potential with broad possible applications.
Laromestrocel development programs target hypoplastic left heart syndrome, Alzheimer’s disease, pediatric dilated cardiomyopathy and aging-related frailty, and the company reports that these programs have received five U.S. Food and Drug Administration designations, including orphan drug, fast track, and rare pediatric disease for the hypoplastic left heart syndrome program, and RMAT and fast track for the Alzheimer’s program.
